Ethan Russo, MD, is a board-certified neurologist and psychopharmacology researcher. He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, in Medicine at the University of Washington, and as visiting professor, Chinese Academy of Sciences. He is currently Past-President of the International Cannabinoid Research Society, and is former Chairman of the International Association for Cannabinoid Medicines.
Journal of the National Cancer Institute, 8 April 2015
—
BACKGROUND: Pharmacological activation of cannabinoid receptors elicits antitumoral responses in different cancer models. However, the biological role of these receptors in tumor physio-pathology is still unknown. METHODS: We analyzed CB2 cannabinoid receptor protein expressio…
Oncology Reports, April 2015
—
In the early stages, prostate cancer is androgen‑ dependent; therefore, medical castration has shown significant results during the initial stages of this pathology. Despite this early effect, advanced prostate cancer is resilient to such treatment. Recent evidence shows that…
Clinical Researcher, April 2015
—
Although cannabis is primarily viewed by the public as a recreational drug or agent of abuse, its medical application spans recorded history.1,2 Evolution has yielded a cannabis plant that produces a family of some 100 chemicals called phytocannabinoids (“plant cannabinoids”)…
Journal of Clinical Pharmacy and Therapeutics, April 2015
—
WHAT IS KNOWN AND OBJECTIVE: Antiepileptic drugs often produce serious adverse effects, and many patients do not respond to them properly. Phytocannabinoids produce anticonvulsant effects in preclinical and preliminary human studies, and appear to produce fewer adverse effects…
Clinical Pharmacology & Therapeutics, 8 March 2015
—
Given the lack of effective treatments for late-onset Alzheimer’s disease (LOAD) and the substantial burden on patients, families, health care systems, and economies, finding an effective therapy is one of the highest medical priorities. The past few years have seen a growing…
Annals of Allergy, Asthma & Immunology, March 2015
—
Passage of legislation in Washington, Colorado, Oregon, Alaska, and the District of Columbia allowing recreational use of marijuana, despite federal regulation to the contrary, highlights the continued debate surrounding this unconventional plant. Allergies to marijuana are no…
The Lancet Psychiatry, March 2015
—
BACKGROUND: The risk of individuals having adverse effects from drug use (eg, alcohol) generally depends on the frequency of use and potency of the drug used. We aimed to investigate how frequent use of skunk-like (high-potency) cannabis in south London affected the associatio…
The British Journal of Cardiology, March 2015
—
Cannabis has been employed medicinally and recreationally for thousands of years, but it was not until the 1960s that the structure and pharmacology of its primary phytocannabinoid components, cannabidiol (CBD) and tetrahydrocannabinol (THC) were identified, and another genera…
Pediatrics, March 2015
—
This policy statement is an update of the American Academy of Pediatrics policy statement “Legalization of Marijuana: Potential Impact on Youth,” published in 2004. Pediatricians have special expertise in the care of children and adolescents and may be called on to advise legi…
International Reviews of Immunology, 2015
—
The impact of the endogenous cannabinoids (AEA, 2-AG, PEA, and virodamine) on the immune cell expressed cannabinoid receptors (CB1, CB2, TRPV-1, and GPR55) and consequent regulation of immune function is an exciting area of research with potential implications in the preventio…
Pharmacology & Pharmacy, 2015
—
Cannabidiol (CBD), a major constituent of Cannabis, has been shown to be a powerful anti-in- flammatory and anti-anxiety drug, without exerting a psychotropic effect. However, when given either intraperitoneally or orally as a purified product, a bell-shaped dose-response was…